Skip to search formSkip to main contentSkip to account menu

ZD 6126

Known as: Vascular Disrupting Agent ZD6126, ZD-6126, ZD6126 
A water-soluble phosphate prodrug of N-acetylcolchinol with potential antiangiogenesis and antineoplastic activities. ZD-6126 is converted in vivo… 
National Institutes of Health

Related topics

Related topics

3 relations
ANG453Microtubule Processfluorouracil/leucovorin calcium/oxaliplatin/ZD6126

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2007
Review
2007
Small molecule vascular disrupting agents: potential new drugs for cancer treatment.
Vascular disrupting agents (VDAs) are a new class of potential anticancer drugs that selectively destroy tumor vasculature and… 
2007
2007
Correlation of MRI biomarkers with tumor necrosis in Hras5 tumor xenograft in athymic rats.
Magnetic resonance imaging (MRI) can measure the effects of therapies targeting the tumor vasculature and has demonstrated that… 
Highly Cited
2006
Highly Cited
2006
Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors.
PURPOSE ZD6126 is a novel vascular-targeting agent that induces selective effects on the morphology of endothelial cells by… 
2005
2005
Targeting Established Tumor Vasculature: A Novel Approach to Cancer Treatment
The selective targeting of established tumor vasculature represents an attractive new anticancer drug strategy, distinct from… 
2005
2005
Targeting the tumor vasculature: enhancing antitumor efficacy through combination treatment with ZD6126 and ZD6474.
BACKGROUND The antitumor efficacy of combination therapy of the vascular disrupting agent ZD6126 and antiangiogenic agent ZD6474… 
2005
2005
Acute tumor response to ZD6126 assessed by intrinsic susceptibility magnetic resonance imaging.
The effective magnetic resonance imaging (MRI) transverse relaxation rate R(2)* was investigated as an early acute marker of the… 
Highly Cited
2003
Highly Cited
2003
Vascular-targeting activity of ZD6126, a novel tubulin-binding agent.
The tubulin-binding agent ZD6126 is a novel vascular-targeting agent in clinical development for the treatment of solid tumors… 
Review
2003
Review
2003
Angiogenesis inhibitors under study for the treatment of lung cancer.
Highly Cited
2003
Highly Cited
2003
Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response.
Highly Cited
2002
Highly Cited
2002
ZD6126: a novel small molecule vascular targeting agent.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)